Key facts
- It has raised $40.0M; the latest was Early Stage VC ($40.0M) in Feb 2026.
- Notable investors include Hefei Industry Investment Group, Shanghai Zhonghuijin Investment Group, Shanghai Songjiang State-owned Assets Investment, Betta Pharmaceuticals, Feixi County Industrial Park Investment Holding (Group) — 10 tracked in total.
- Status: Privately Held (backing).
Investors
10- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Tuosheng Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Tuosheng Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tuosheng Pharma
Manufacturer of antibody-drug conjugate therapeutics intended to support targeted and differentiated cancer treatment development. The company offers proprietary payload engineering, multi-target conjugation technologies, and integrated development capabilities, thereby enabling pharmaceutical partners and oncology treatment providers to advance safer and more effective anticancer drugs.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Tuosheng Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tuosheng Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tuosheng Pharma in its N-PORT filings yet. We sweep new filings monthly.